Drug screening method based on structural fragments, tetracyclic diterpenoid compounds and applications

Through the structural fragment screening method without the crystal structure of the receptor protein, the parent nucleus and multi-ring structural fragments were screened out, and the design molecules were obtained through functional group modification, which solved the problems of high cost and low efficiency in the existing technology and achieved efficient drugs Molecular development and screening to obtain drugs with anti-inflammatory and anti-metabolic syndrome activities.

CN114420202BActive Publication Date: 2024-11-22HUAZHONG AGRI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210091047.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-26
Publication Date
2024-11-22
Estimated Expiration
2042-01-26

AI Technical Summary

Technical Problem

Existing structural fragment-based drug discovery methods require crystal structure diagrams of receptor proteins, resulting in high cost, low efficiency, and difficulty in accurately determining structural fragments that affect compound activity.

Method used

By decomposing the molecules to be improved with biological activity into structural fragments, the parent nucleus structure and polycyclic structure are screened as landmark structural fragments, without knowing the crystal structure of the receptor protein, the compound structure is screened, and the design is obtained through functional group modification molecules make their structural similarity higher than those of the leading molecules.

Benefits of technology

It improves the efficiency of drug molecule development, reduces the cost of drug molecule screening, improves the rationality and success rate of drug screening, and obtains designed molecules with activities such as anti-inflammatory and anti-metabolic syndrome, such as 15-carbonyl-steviol.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114420202B_ABST
    Figure CN114420202B_ABST
Patent Text Reader

Abstract

The present invention discloses a drug screening method based on structural fragments, tetracyclic diterpenoid compounds and applications. The method comprises: (1) fragmenting the lead molecule structure into structural fragments, screening out the mother core structure and the polycyclic structure; (2) using the mother core and the polycyclic structure fragments as screening conditions, searching for a collection of compounds as a collection of candidate raw material molecules; (3) selecting one or more raw material molecules, comparing them with the lead molecule, and modifying the raw material molecules with functional groups to obtain a designed molecule, so that the structural similarity between the designed molecule and the lead molecule is higher than the structural similarity between the raw material molecule and the lead molecule. The drug screening method based on structural fragments provided by the present invention does not require a receptor protein crystallization diagram, can improve the efficiency of drug molecule development, and reduce the cost of drug molecule screening. Taking Oridonin (Ori) as the lead molecule, the designed drug molecule has obvious anti-inflammatory and anti-metabolic syndrome activities.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and more specifically, relates to a drug screening method based on structural fragments, tetracyclic diterpenoid compounds and applications. Background Art

[0002] The field of drug research and development has always been a key area based on the great cause of human health. Since the rise of combinatorial chemistry in the 1990s, drug researchers in various countries have devoted a lot of manpower and material resources to drug research and development based on combinatorial chemistry, but the output in recent years has not been as high as expected. Natural products and their derivatives have always been the focus of drug research and development workers. Through the data analysis of new drugs approved by the FDA in the 35 years from 1981 to 2014, it can be found that nearly 63% of new drugs are derived from natural products or developed based on natural products. This data directly reflects the importance of natural product drugs in the field of drug discovery. Although combinatorial chemistry has demonstrated its good application prospects, natural products still have an important role and irreplaceable position in the new drug research and development. Therefore, applying combinatorial chemistry to new drug research and development by combining with natural product drugs has great application prospects.

[0003] In the development of natural medicines, the traditional screening method is high throughput screening (HTS). High throughput screening is a method based on in vitro simulation of the mutual binding between a huge library of natural compounds and drug targets, and then verifying the compounds based on the simulation results. Traditional high throughput screening methods have many disadvantages, such as poor quality of screening results. HTS can often obtain many target compounds, and most of these compounds are invalid compounds; the screening process is complicated and time-consuming. The HTS process is often accompanied by multiple processes, and each process requires a large number of target compounds to be verified one by one, which places extremely high demands on the test method and is time-consuming and costly; the screening theory is not completely rational. It only uses simulation software to simulate the binding of compounds and target proteins to screen a huge library of compounds, which will result in a large number of false positive results.

[0004] Fragment-based drug discovery (FBDD) emerged as an alternative to HTS in the 1990s and quickly became a powerful screening method in natural product drug development. FBDD is mainly composed of two modules: the detection module and the compound library module. The core of FBDD is the fragmentation of compound drugs. Through reasonable fragmentation of drugs, even decomposing drugs into discrete functional groups, and then screening high-affinity elements of different pharmacodynamic structures through computational analysis methods of ligand binding. By properly optimizing the binding sites of high-affinity elements, they are then incorporated into single entity molecules to produce compounds with high affinity.

[0005] The FBDD method is more effective than the HTS method and is easier to obtain small molecule drugs with biological activity, which has long been reflected in previous studies. In addition to overcoming the disadvantages of HTS, the FBDD method has many other advantages. The operating object of FBDD is the structure fragment library. Compared with the complex compound structure, the molecular fragments are simpler, and the structure fragment library is much smaller than the compound library; in addition, more chemical diversity can be generated by screening and recombining the molecular fragment library. In addition, the screening of pharmacodynamic structural fragments with high affinity can increase the hit rate of drug screening. Studies have shown that the hit rate of FBDD is 10-1000 times higher than that of HTS.

[0006] However, drug discovery based on structural fragments usually requires a crystal structure diagram of the receptor protein. However, the identification and purification of the receptor protein is costly and inefficient, which affects the application of drug discovery based on structural fragments. Summary of the invention

[0007] In view of the above defects or improvement needs of the prior art, the present invention provides a drug screening method based on structural fragments, tetracyclic diterpenoid compounds and applications, the purpose of which is to select the mother core structure and polycyclic structure that are closely related to the biological activity of natural product molecules as the iconic structural fragments through the observation of the structural fragments, without the need to know the crystal structure of the receptor protein, to perform compound structure screening, thereby solving the technical problems that the existing drug discovery method based on structural fragments requires the crystal structure diagram of the receptor protein to determine the iconic structural fragments, which is costly, expensive and inefficient.

[0008] To achieve the above object, according to one aspect of the present invention, a drug screening method based on structural fragments is provided, which comprises the following steps:

[0009] (1) Using a molecule to be improved with specific biological activity as a lead molecule, fragmenting its molecular structure into structural fragments, screening out the mother core structure as a mother core screening marker structural fragment, and screening out the multi-ring structure as a binding screening marker structural fragment;

[0010] (2) using the parent core screening marker structural fragment obtained in step (1) and one or more combined screening marker structural fragments as screening conditions, respectively, and searching in a natural product database for a set of compounds containing all screening marker structural fragments of the screening conditions as a set of candidate raw material molecules;

[0011] (3) selecting one or more raw material molecules from the raw material molecule set obtained in step (2), comparing them with the lead molecule obtained in step (1), and performing functional group modification on the raw material molecules to obtain one or more designed molecules, so that the structural similarity between the designed molecules and the lead molecule is higher than the structural similarity between the raw material molecules and the lead molecule.

[0012] Preferably, in the drug screening method based on structural fragments, the polycyclic structure is a polycyclic structure sharing 3 or more atoms, especially a polycyclic structure sharing 3 or more carbon atoms.

[0013] Preferably, in the structural fragment-based drug screening method, the polycyclic structure is a polycyclic structure sharing 6 or more carbon atoms, preferably a polycyclic structure sharing 8 or more carbon atoms.

[0014] Preferably, in the drug screening method based on structural fragments, the raw material molecule selected from the raw material molecule set in step (3) is:

[0015] Based on indicators that affect drug development prospects, such as biological content in the host, raw material molecules are selected with the principle of giving priority to those with better drug development prospects.

[0016] Preferably, in the drug screening method based on structural fragments, the step (3) is to make the structural similarity between the designed molecule and the lead molecule higher than the structural similarity between the raw material molecule and the lead molecule, and the specific steps are as follows:

[0017] The active functional groups of the lead molecule are determined by analyzing the physiological model or molecular docking model of the lead molecule, and compared with the raw material molecule, different active functional groups are obtained, and the different functional groups are constructed at the corresponding positions of the raw material molecule mother nucleus.

[0018] According to another aspect of the present invention, a designed molecule obtained by the drug screening method based on structural fragments is provided, which has a core structure shown in formula (1) and a polycyclic structure shown in formula (2);

[0019]

[0020] Preferably, the designed molecule is: 15-carbonyl-stevioside.

[0021] According to another aspect of the present invention, there is provided an application of the designed molecule, characterized in that it is applied to prepare anti-inflammatory drugs or anti-metabolic syndrome drugs.

[0022] Preferably, the designed molecules are used to prepare anti-acute peritonitis drugs, anti-acute gouty arthritis drugs, anti-chronic inflammation drugs, and for preparing NLRP3 inflammasome-mediated inflammation-related disease therapeutic drugs including neurodegenerative diseases.

[0023] Preferably, the designed molecules are used to prepare drugs for treating obesity and type 2 diabetes.

[0024] In general, the above technical solutions conceived by the present invention can achieve the following beneficial effects compared with the prior art:

[0025] The drug screening method based on structural fragments provided by the present invention does not require a receptor protein crystal map and can more accurately determine the structural fragments of natural product molecules that affect the activity of the compound or have the potential to be transformed into drugs through structural analysis, thereby improving the efficiency of drug molecule development and reducing the cost of drug molecule screening.

[0026] The optimal scheme, combined with other indicators that affect the drug development prospects, such as the biological content in the host, is used to select raw material molecules, which can further improve the rationality of drug screening and increase the success rate of drug development.

[0027] The drug molecules designed with Oridonin (Ori) as the lead molecule have obvious anti-inflammatory activity, especially anti-chronic inflammation, and anti-metabolic syndrome, such as obesity and type II diabetes. In particular, 15-carbonyl-stevioside can be used to prepare drugs for acute peritonitis, acute gouty arthritis, chronic inflammation, and for the preparation of drugs for the treatment of NLRP3 inflammasome-mediated inflammation-related diseases including neurodegenerative diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 Flow chart of the design method based on lead compounds provided in Example 1 of the present invention.

[0029] Figure 2 is the structural formula of the lead molecule Oridonin (Ori) provided in Example 1;

[0030] Figure 3They are natural diterpenoid compounds with significant anti-tumor and / or anti-inflammatory and / or antibacterial activities, namely Ori, Pt. semipinnata 5F, Pt. semipinnata 6F and esculenta acetogenin.

[0031] Figure 4 It is the extraction of the core structure and biologically active structure of the lead molecule Ori in Example 1.

[0032] Figure 5 This is the screening of natural products based on the structural fragments of Ori in Example 1. (a) Ori structural fragments. (b) According to the structural fragments, the corresponding sub-fragment sets LABEL 1 (1584 natural products) and LABEL 2 (1654 natural products) were screened and constructed in the natural product library COCONUT (a total of 422,966 natural products), and the intersection of Label 1 and Label 2 was taken as the candidate compound library (candidate) (1033 natural products). (c) The molecular structural formula of stevioside obtained by screening effective candidate compounds combined with biological content analysis.

[0033] Figure 6 This is the structural modification scheme of the candidate small molecule steviol glycoside in Example 1.

[0034] FIG. 7 is a diagram showing the structural identification results of ST-2 provided in Example 1, wherein a is the hydrogen nuclear magnetic resonance spectrum and b is the carbon nuclear magnetic resonance spectrum.

[0035] FIG8 is a diagram showing the structural identification results of ST-3 provided in Example 1, wherein a is the hydrogen nuclear magnetic resonance spectrum and b is the carbon nuclear magnetic resonance spectrum.

[0036] FIG9 is a diagram showing the structural identification results of ST-4 provided in Example 1, wherein a is the hydrogen nuclear magnetic resonance spectrum and b is the carbon nuclear magnetic resonance spectrum.

[0037] FIG10 is a diagram showing the structural identification results of ST-5 provided in Example 1, wherein a is the hydrogen nuclear magnetic resonance spectrum and b is the carbon nuclear magnetic resonance spectrum.

[0038] FIG11 is a diagram showing the structural identification results of ST-6 provided in Example 1, wherein a is the hydrogen nuclear magnetic resonance spectrum and b is the carbon nuclear magnetic resonance spectrum.

[0039] Fig.12The effect of ST-4 and ST-2 on NLRP3 inflammasome activation in BMDMs cells in Example 1. After BMDMs cells were pretreated with lipopolysaccharides (LPS) (200 ng / mL) for 3 h, different compounds were added for 30 min. The model group was treated with an equal amount of solvent and then Nigericin (10 μM) was added for 30 min. The IL-1β content in the supernatant was detected by enzyme linked immunosorbent assay (ELISA).

[0040] Fig.13 The effects of ST-4 and ST-2 on tumor cell viability in Example 2. (a), (b), and (c) are the effects of ST-2 on the viability of different tumor cell lines A549, HepG2, and MCF-7, respectively. (d), (e), and (f) are the effects of ST-4 on the viability of different tumor cell lines A549, HepG2, and MCF-7, respectively.

[0041] Fig.14 Effects of ST-4 and ST-2 on macrophage viability in Example 2. (a) and (b) are the effects of ST-2 on the viability of immortalized bone marrow-derived macrophages (iBMDMs) and THP-1 cells, respectively. (c) and (d) are the effects of ST-4 on the viability of iBMDMs and THP-1 cells, respectively.

[0042] Fig.15The effect of ST-4 on NLRP3 inflammasome activation in BMDMs cells in Example 3. (a, ce) After LPS (200 ng / mL) was pretreated with BMDMs cells for 3 h in advance, different concentrations of ST-4 (0.5, 1, 2 μM) were added for 30 min, and the model group was treated with an equal amount of solvent, and then Nigericin (10 μM) was added for 30 min. ELISA was used to detect the contents of IL-1β, IL-18, IL-6 and TNF-α in the cell culture supernatant. (b) After LPS (200 ng / mL) was pretreated with BMDM cells for 3 h in advance, different concentrations of ST-4 (0.5, 1, 2 μM) were added for 30 min, and the model group was treated with an equal amount of solvent, and then Nigericin (10 μM) was added for 30 min. Western Blot (WB) was used to detect the expression of IL-1β and caspase-1 in cell culture supernatant (SN), and the expression of IL-1β precursor (pro-IL-1β), caspase-1 precursor (pro-caspase-1) and β-Tublin in cell lysate (input).

[0043] Fig.16 The effect of ST-4 on NLRP3 inflammasome activation caused by adenosine triphosphate (ATP) and monosodium urate (MSU) in Example 3. After LPS (200 ng / mL) was pretreated with BMDMs cells for 3 h in advance, different concentrations of ST-4 (0.5, 1, 2 μM) were added for 30 min, and the model group was treated with an equal amount of solvent, and then ATP (2.5 mM) (a) was added for 30 min or MSU (200 μg / ml) (b) was added for 6 h. The IL-1β content in the cell culture supernatant was detected by ELISA.

[0044] Fig.17The effect of ST-4 on the LPS-activated NF-κB signaling pathway in Example 3. (a) After LPS (200 ng / mL) was pretreated with BMDMs cells for 3 h in advance, different concentrations of ST-4 (0.5, 1, 2 μM) were added for 30 min. Alternatively, different concentrations of ST-4 (0.5, 1, 2 μM) were added to treat BMDMs cells for 30 min, and then LPS (200 ng / mL) was added for 3 h. The model group was treated with an equal amount of solvent, and then Nigericin (10 μM) was added for 30 min. WB was used to detect the expression of IL-1β and caspase-1 in the cell culture supernatant (SN), and the expression of NLRP3, ASC, IL-1β precursor (pro-IL-1β), caspase-1 precursor (pro-caspase-1) and β-Tublin in the cell lysate (input). (bc) After LPS (200 ng / mL) was pretreated for 3 h, different concentrations of ST-4 (0.5, 1, 2 μM) were added to BMDMs cells for 30 min. Alternatively, different concentrations of ST-4 (0.5, 1, 2 μM) were added to BMDMs cells for 30 min, and then LPS (200 ng / mL) was added for 3 h. The model group was treated with an equal amount of solvent, and then Nigericin (10 μM) was added for 30 min. The levels of IL-1β and TNF-α in the cell culture supernatant were detected by ELISA.

[0045] Fig.18 The effect of ST-4 on acute peritonitis in mice induced by MSU in Example 4. (ac) Acute peritonitis was induced by intraperitoneal injection of MSU crystals (1 mg / mouse), ST-4 (20 mg / kg) or Oridonin (20 mg / kg) was intraperitoneally injected 30 minutes before MSU injection, and the control group was injected with an equal volume of solvent for 6 hours. The IL-1β content in mouse serum (a) and peritoneal lavage fluid (b) was detected by ELISA, and the number of neutrophils in peritoneal lavage fluid was detected by blood routine test (c).

[0046] Fig.19 The effect of ST-4 on MSU-induced gouty arthritis in Example 4. (a) ST-4 (20 mg / kg) or Ori (20 mg / kg) was injected into the joint, and the control group was injected with an equal volume of solvent. MSU crystals (0.5 mg / mouse) were injected 30 minutes later, and the joint size at different time points was recorded. (b) The joint was taken out and cultured for 24 hours, and the IL-1β content in the joint culture supernatant was detected by ELISA. (c) Joint swelling of mice 24 hours after MSU induction.

[0047] Fig. 20The effects of ST-4 on the body weight and food intake of obese mice induced by high fat diet (HFD) in Example 4. (a) Daily body weight changes during ST-4 administration intervention. (bc) Body weight (b) and food intake (c) of obese mice induced by HFD for 16 weeks after ST-4 administration intervention for 6 weeks.

[0048] Fig.21 The effects of ST-4 in Example 4 on blood glucose levels, blood glucose tolerance and insulin sensitivity in HFD-induced type 2 diabetic mice. (ab) Fasting blood glucose (a) and fed blood glucose (b) of type 2 diabetic mice induced by HFD for 16 weeks after ST-4 administration for 6 weeks. (cd) Blood glucose tolerance (GTT) (c) and insulin sensitivity (ITT) (d) of type 2 diabetic mice induced by HFD for 16 weeks after ST-4 administration for 6 weeks.

[0049] Fig. 22 The effect of ST-4 on the pathological state of HFD-induced obese mice in Example 4. (a) Body size of obese mice 6 weeks after ST-4 administration for 16 weeks (1: NCD+Vehicle, 2: HFD+Vehicle, 3: HFD+Oridonin (3 mg / kg), 4: HFD+ST-4 (2.5 mg / kg), 5: HFD+ST-4 (5 mg / kg), 6: HFD+ST-4 (10 mg / kg)). (bc) H&E staining of liver tissue (b) and white adipose tissue (c) of obese mice 6 weeks after ST-4 (2.5 mg / kg) administration for 16 weeks, scale bar, 50 μm.

[0050] Fig.23 The effects of ST-4 on the body weight and food intake of normal lean mice in Example 4. (a) Daily body weight changes during ST-4 administration intervention. (bc) Body weight (b) and food intake (c) of normal lean mice 15 days after intraperitoneal injection of ST-4 (10 mg / kg).

[0051] Fig.24 The effects of ST-4 on the body weight and food intake of NLRP3- / -gene-deficient metabolic disorder mice induced by high-fat diet in Example 4. (a) Daily body weight changes during ST-4 administration intervention. (bc) Body weight (b) and food intake (c) of NLRP3- / - obese mice induced by HFD for 16 weeks after ST-4 administration intervention for 6 weeks.

[0052] Fig.25The effect of ST-4 on blood glucose in HFD-induced NLRP3- / -gene-deficient metabolic disorder mice in Example 4. (ab) Fasting blood glucose (a) and fed blood glucose (b) of NLRP3- / -gene-deficient metabolic disorder mice induced by HFD for 16 weeks, and ST-4 was administered for 6 weeks. (cd) Glucose tolerance (GTT) (c) and insulin sensitivity (ITT) (d) of NLRP3- / -gene-deficient metabolic disorder mice induced by HFD for 16 weeks, and ST-4 was administered for 6 weeks.

[0053] Fig.26 This is the effect of ST-4 on the liver and fat of NLRP3- / -gene-deficient metabolic disorder mice induced by HFD in Example 4. H&E staining of liver tissue and adipose tissue of NLRP3- / -gene-deficient metabolic disorder mice induced by HFD for 16 weeks, and ST-4 administration intervention for 6 weeks, scale bar, 50μm.

[0054] Fig. 27 The effect of ST-4 on NLRP3 inflammasome-dependent chronic inflammation in HFD-induced metabolic disorder mice in Example 4. (ac) WT mice and NLRP3- / -gene-deficient mice induced by HFD for 16 weeks, and the content of IL-β in mouse blood (a), liver tissue (b) and adipose tissue (c) after 6 weeks of ST-4 intervention. (d) WT mice and NLRP3- / -gene-deficient mice induced by HFD for 16 weeks, and the expression of caspase-1 in mouse adipose tissue was detected by WB after 6 weeks of ST-4 intervention.

[0055] Fig.28 The effect of ST-4 on the level of systemic inflammation in HFD-induced metabolic disorder mice in Example 4. (ac) WT mice and NLRP3- / -gene-deficient mice induced by HFD for 16 weeks, and the content of TNF-α in mouse serum (a), liver tissue (b) and adipose tissue (c) after 6 weeks of ST-4 administration. (df) WT mice and NLRP3- / -gene-deficient mice induced by HFD for 16 weeks, and the content of MCP-1 in mouse serum (d), liver tissue (e) and adipose tissue (f) after 6 weeks of ST-4 administration.

[0056] Fig.29The effects of long-term treatment with ST-4 in Example 4 on the physiological parameters of normal mice. (a) Body weight changes during intraperitoneal injection of ST-4 (10 mg / kg). (b) Initial body weight of experimental mice and body weight of mice 3 months after intraperitoneal injection of ST-4 (10 mg / kg). (c) Food intake of mice after three months of intraperitoneal injection of ST-4 (10 mg / kg). (de) Fasting blood glucose (d) and fed blood glucose (e) of mice after three months of intraperitoneal injection of ST-4 (10 mg / kg).

[0057] Fig.30 The effects of long-term treatment with ST-4 on blood biochemical indices of normal mice in Example 4. (ag) Levels of ALT (a), AST (b), CRE (c), UREA (d), LDH (e), ALP (f), and T-BIL (g) in mouse serum three months after intraperitoneal injection of solvent or ST-4 (10 mg / kg). DETAILED DESCRIPTION

[0058] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0059] There are many compound resources with excellent biological activity in nature, such as the broad-spectrum and potent anti-cancer drug paclitaxel and the potent anti-malarial drug artemisia annua. However, the availability of most natural product drugs with significant efficacy is extremely poor, which has greatly limited the application prospects of many natural product drugs.

[0060] The present invention provides a drug screening method based on structural fragments, comprising the following steps:

[0061] (1) A molecule to be improved with specific biological activity is used as a lead molecule, and its molecular structure is fragmented and decomposed into structural fragments, and the mother core structure is screened out as the mother core screening marker structural fragment, and the multi-ring structure is screened out as the binding screening marker structural fragment; wherein:

[0062] The parent core structure is the basic skeleton structure common to a class of active molecules, such as pentacyclic triterpene structure and tetracyclic diterpene structure. The chemical composition of organic drugs is composed of a basic parent core plus functional groups. The parent core structure is the basic characteristic of drug properties, so it is suitable for screening marker structural fragments.

[0063] A polycyclic structure, preferably a polycyclic structure sharing 3 or more atoms, especially a polycyclic structure sharing 3 or more carbon atoms, will bring a three-dimensional conformation to the molecule, largely determine the three-dimensional morphology of the entire molecule, thereby determining the ability to interact with active molecules and targets, and to a large extent affecting its biological activity, so it is suitable for screening marker structural fragments; statistics show that common three-dimensional structures that affect activity in natural product structures include: polycyclic structures sharing 6 or more carbon atoms, and polycyclic structures sharing 8 or more carbon atoms; the ring structure here refers to a structure that can form a closed path through chemical bonds within the molecular structure. When a three-dimensional structure is formed, there will be a conformation in which at least three rings share C atoms, and any two of the loops share at least 2 atoms to form a polycyclic structure. When there are two rings sharing 3 or more atoms in the three-dimensional structure, the structure is called a polycyclic structure sharing 3 or more atoms; similarly, when there are two rings sharing N atoms, the structure is called a polycyclic structure sharing N atoms. In order to make structural comparison more convenient, the number of atoms with the largest number of atoms shared between multiple rings in the polycyclic structure fragment is taken to define the number of atoms shared by the polycyclic structure. For example, when the first to third rings share atoms to form a three-dimensional conformation, the first ring and the second ring share N1 atoms, the second ring and the third ring share N2 atoms, the first ring and the third ring share N3 atoms, and N1≥N2≥N3, then the structural fragment is called a polycyclic structure sharing N1 atoms.

[0064] (2) using the parent core screening marker structural fragment obtained in step (1) and one or more combined screening marker structural fragments as screening conditions, respectively, and searching in a natural product database for a set of compounds containing all screening marker structural fragments of the screening conditions as a set of candidate raw material molecules;

[0065] The natural product database may be a public database, such as COCONUT (Collection of open natural products), or may be collected on its own. Appropriate binding screening marker structure fragments may be selected based on the screening results. If there are too many screening results, the number of binding screening marker structure fragments used as screening conditions may be increased, and vice versa, the number of binding screening marker structure fragments used as screening conditions may be reduced.

[0066] (3) selecting one or more raw material molecules from the raw material molecule set obtained in step (2), comparing them with the lead molecule obtained in step (1), and performing functional group modification on the raw material molecules to obtain one or more designed molecules, so that the structural similarity between the designed molecules and the lead molecule is higher than the structural similarity between the raw material molecules and the lead molecule;

[0067] The raw material molecules selected from the raw material molecule set are preferably:

[0068] Based on indicators that affect drug development prospects, such as biological content in the host, raw material molecules are selected according to the principle of giving priority to those with better drug development prospects;

[0069] The method of making the structural similarity between the designed molecule and the lead molecule higher than the structural similarity between the raw material molecule and the lead molecule preferably comprises the following specific steps:

[0070] The active functional groups of the lead molecule are determined by analyzing the physiological model of the lead molecule or the molecular docking model, and compared with the raw material molecule, a different active functional group is obtained, and the functional group with the difference is constructed at the corresponding position of the parent nucleus of the raw material molecule. Since the lead molecule and the raw material molecule have the same parent nucleus, the corresponding position of the active functional group can be determined to obtain the designed molecule, ensuring that the similarity between the designed molecule and the lead molecule is higher than the similarity between the raw material molecule and the lead molecule, that is, the designed molecule is more similar to the lead molecule than the raw material molecule.

[0071] (4) Subjecting the designed molecules to drug efficacy and safety experiments to develop them into drug molecules.

[0072] According to the drug screening method based on structural fragments provided by the present invention, a tetracyclic diterpenoid candidate drug compound with anti-inflammatory effect is screened, which has a mother core structure shown in formula (1) and a multi-ring structure shown in formula (2);

[0073]

[0074] Specifically: 15-carbonyl-stevioside.

[0075] The compound is used to prepare anti-inflammatory drugs, such as anti-acute peritonitis drugs, anti-acute gouty arthritis drugs, preferably for preparing anti-chronic inflammation drugs, for preparing NLRP3 inflammasome-mediated inflammation-related disease treatment drugs including neurodegenerative diseases; or metabolic syndrome treatment drugs, such as obesity and type 2 diabetes.

[0076] Inflammatory diseases are a very common disease in people's lives. In the field of traditional Chinese medicine, inflammation usually manifests as symptoms such as redness, swelling, heat, pain, and functional disorders. In the field of immunity and metabolism, inflammation is associated with a variety of autoinflammatory and autoimmune diseases, including neurodegenerative diseases and metabolic disorders. In chronic inflammatory reactions, the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome plays a key role and is closely related to various chronic diseases. Oridonin (Ori) derived from the traditional Chinese medicine Rabdosia rubescens (Hemsl.) Hara is a specific inhibitor of NLRP3 inflammasome. It can not only effectively inhibit the activation of NLRP3 inflammasome in vitro, but also show good therapeutic effects in several types of mouse inflammatory pathological models associated with NLRP3 inflammasome. However, the low biological content of Ori and the overly complex total chemical synthesis limit its further application. Using Ori as the lead molecule, according to the drug screening method based on structural fragments provided by the present invention, the designed molecule 15-carbonyl-stevioside was obtained, which has good anti-inflammatory activity and drug development prospects.

[0077] The following are examples:

[0078] Taking a tetracyclic diterpenoid compound as an example, a designed molecule is obtained according to the method provided by the present invention. The tetracyclic diterpenoid compound has the same mother core structure as the lead molecule, and also has the same structure as the binding site of the lead molecule and the target protein, as well as the active functional groups possessed by the lead molecule and the natural product with similar biological activity.

[0079] Example 1 The drug screening method based on structural fragments provided by the present invention was used to improve the lead molecule Ori to screen for anti-inflammatory active molecules, such as Figure 1 As shown, the following steps are included:

[0080] (1) Using a molecule to be improved with specific biological activity as a lead molecule, fragmenting its molecular structure into structural fragments, screening out a mother core structure as a mother core screening marker structural fragment, and screening out a multi-ring structure as a combination screening marker structural fragment; specifically:

[0081] Ori was selected as the natural product molecule to be improved, i.e., the lead molecule;

[0082] Ori is an active diterpene natural product extracted from the plant Rubescens rubescens of the Lamiaceae family. Figure 2As shown. Although Ori has good anti-inflammatory and anti-tumor activities, its low biological content and complex chemical synthesis pathway severely limit its application prospects. Ori is not a drug molecule with excellent drug properties, but it is a good lead molecule for drug research.

[0083] By analyzing the molecular structure of Ori compounds and the structural sites where they exert anti-inflammatory activity and bind to target proteins, the parent nucleus structure of Ori was extracted as a parent nucleus screening marker structural fragment (Label 1) and the polycyclic structure as a binding screening marker structural fragment (Label 2). Figure 3 shown.

[0084] (2) using the parent core screening marker structural fragment obtained in step (1) and one or more combined screening marker structural fragments as screening conditions, respectively, searching a natural product database for a set of compounds containing all screening marker structural fragments of the screening conditions as a set of candidate raw material molecules; specifically:

[0085] The extracted structural fragments were simulated and compared with the COCONUT database to construct the corresponding structural fragment library, and the intersection of the structural fragment library was taken as the candidate compound library. The effective candidate compound library, that is, the set of alternative raw material molecules, was further constructed by sorting out the basic information of the candidate compounds. Among them, there were 1584 molecules containing Label 1 structure, 1654 molecules containing Label 2 structure, and a total of 1033 molecules containing both Label 1 and Label 2 structures, constituting the set of alternative raw material molecules.

[0086] (3) selecting one or more raw material molecules from the raw material molecule set obtained in step (2), comparing them with the lead molecule obtained in step (1), and performing functional group modification on the raw material molecules to obtain one or more designed molecules, so that the structural similarity between the designed molecules and the lead molecule is higher than the structural similarity between the raw material molecules and the lead molecule; specifically:

[0087] The availability of effective candidate compounds was analyzed in combination with the host biological content, etc., and screening was performed. Since the availability of compounds restricts the possibility of drug development and the cost of drug preparation, this embodiment finally preferred to select steviol glycoside, a natural diterpene derivative from the chrysanthemum crop stevia, as the raw material molecule. The structure of steviol glycoside is as follows Figure 5 shown.

[0088] By analyzing the physiological model or molecular docking model of the lead molecule (Ori) and other small molecules with similar biological activities, the active functional groups of the lead molecule are screened and determined, and compared with the effective candidate small molecules, the active functional groups with differences are obtained and introduced into the effective candidate small molecules, such as Figure 6 shown.

[0089] (4) Subjecting the designed molecules to drug efficacy and safety experiments to develop them into drug molecules.

[0090] Anti-inflammatory activity cell experiment:

[0091] By simulating the physiological model of inflammation in which NLRP3 inflammasomes are induced to activate and express the inflammatory factor interleukin 1β (IL-1β) in mouse bone marrow-derived macrophages (BMDMs), the anti-inflammatory activity of the designed tetracyclic diterpenoid compound: 15-carbonyl-stevioside (ST-4) was screened and verified.

[0092] Pharmacological experimental methods and results of compounds inhibiting the activation of NLRP3 inflammasome in mouse bone marrow-derived macrophages (BMDMs) to express and secrete the inflammatory factor interleukin 1β (IL-1β):

[0093] 1) Isolation and culture of mouse bone marrow-derived macrophages (BMDMs): In the animal room, take 6-week-old mice, kill them by cervical dislocation, remove the two hind legs of the mice with sterile scissors, remove the muscles and leave the leg bones, and place the mouse carcasses and other garbage in the mouse morgue. Take the mouse leg bones to the cell room clean bench, soak the scissors and tweezers in 75% alcohol, prepare culture medium, PBS, 20ml syringe and 0.65mm medical needle. Wash the mouse leg bones three times with PBS, fill the 20mL syringe with DMEM culture medium, replace it with a 0.65mm medical needle, grab the bones with tweezers, cut them from both ends with scissors, and then use a syringe to blow the bone marrow into a 50ml centrifuge tube, repeat several times until all the bone marrow is flushed out and the bones turn from red to white, centrifuge at 1500rpm for 5min. Discard the supernatant, resuspend with 1ml of red blood cell lysis buffer, and repeatedly blow, then let it stand for 2min to lyse the red blood cells, then add 9ml of normal DMEM medium for neutralization, 1500rpm, centrifuge for 5min. Discard the supernatant, resuspend with DMEM containing 20ng / mL M-CSF medium or L929 culture supernatant (40ml medium resuspended per mouse, L929 culture supernatant content 30%), and then transfer to non-treated culture dishes for culture (10ml per dish). After 6-7 days, the cell state can be observed, and it is long spindle-shaped, indicating that the state is good and can be used for subsequent experiments.

[0094] 2) Analysis of NLRP3 inflammasome activation and anti-inflammatory activity of compounds: BMDMs on day 6-7 of differentiation, discard the supernatant, wash once with PBS, add 10 ml of PBS containing 1% EDTA for digestion, and after 1-2 min, pipette the cells and transfer them to a 50 ml centrifuge tube and centrifuge at 1500 rpm for 10 min. Discard the supernatant, resuspend with 10 ml of culture medium, and then count to 5×10 6 / ml, then plated into 12-well plates, 1ml / well, overnight. Prepare Opti-MEM containing 1% FBS and 200ng / ml LPS (500μl per well), discard the supernatant, add the prepared culture medium for pre-stimulation, and the stimulation time is 3h. Add drug treatment for 30min. Add the stimulator Nigericin (10μM) to stimulate for 0.5h. Collect the supernatant into a 1.5ml EP tube, centrifuge at 13000rpm for 5min to remove dead cells, and then transfer to a new 1.5ml EP tube, and use it directly for Elisa to detect cytokines. Set up three replicates for each concentration, and set PBS as a blank control, and set 2uM concentration of Ori as a positive control to analyze the inhibitory effect of different concentrations of drugs on the expression and secretion levels of IL-1β.

[0095] like Fig.12 The results showed that ST-4 had the best inhibitory effect on NLRP3 inflammasome activation, and its activity was better than that of the positive control Ori. In addition, ST-6 (structure as shown in the attached Figure 6 also showed an inhibitory effect similar to that of Ori.

[0096] Example 2 The effects of the tetracyclic diterpene compound ST-4 and its precursor candidate small molecules provided by the present invention on the activity of tumor cells and macrophages include the following steps:

[0097] S1. Cell recovery and culture: Preheat the water bath to 37°C, then take out the frozen cells (A549, HepG2 and MCF-7; iBMDMs and THP-1) from the liquid nitrogen tank and place them in a 37°C water bath until they melt. After the cells melt, transfer them to a 50ml centrifuge tube, then add 10ml of normal complete medium (90% DMEM + 10FBS + 1% double antibody) to A549, HepG2, MCF-7 and iBMDMs, and add their proprietary complete medium (90% RPMI-1640 + 10% FBS + 1% double antibody + 0.05mM / L β-mercaptoethanol) to THP-1 cells, mix gently, and centrifuge at 1000rpm for 5min. Discard the supernatant, add 10ml of fresh normal medium to resuspend the cells, then transfer to an appropriate culture volume and place in a cell culture incubator for culture. Observe the cells the next day. If there are many dead cells, the cell culture medium can be replaced. When the cell abundance is 80-90%, discard the culture supernatant, wash three times with PBS to remove the residual culture medium, then add trypsin to digest for 2 minutes, then add normal culture medium to neutralize, and centrifuge at 1000rpm for 5 minutes. Discard the supernatant, add 10ml normal culture medium to resuspend, take 2mL for passage, use the rest for experiment or discard, and fill up to 10mL with normal culture medium. When the cells are in good condition after 2-3 generations, use the MTT method to detect the effect of the compound on cell viability.

[0098] MTT method to detect cell viability: 1×10 4 Cells / well were inoculated into 96-well cell culture plates and cultured at 37°C, 5% CO2, and 100% humidity. When the cells grew to 80-90%, different concentrations of compounds were added for 24 hours. Cells treated with the corresponding solvents were used as negative controls. The culture medium of each well was removed, washed once with sterile PBS, and then 100 μL of culture medium containing MTT (10 mL of culture medium containing 1 mL of MTT solution (5 mg / mL)) was added, and the cells were placed in an incubator and continued to be cultured for 4 hours. The culture medium in each well was discarded, 200 μL of dimethyl sulfoxide (DMSO) was added, protected from light, and gently shaken for 10 minutes. The absorbance at 570 nm and 630 nm was detected by an enzyme reader. Three independent experiments were performed for each compound, and the relative cell viability (%) was calculated:

[0099]

[0100] Effects of ST-4 and its precursor candidate small molecule ST-2 on tumor cells Fig.13 As shown, the precursor candidate small molecule ST-2 is as shown Figure 6 As shown in the results, ST-2 without a D-cycloenone structure had no effect on the vitality of the three cancer cells, while ST-4 with a D-cycloenone structure showed a certain inhibitory effect on the three tumor cell lines (IC50 was 55.39μM, 72.13μM, and 64.07μM, respectively). The results show that after ST-4 forms a D-cycloenone structure in its molecular structure, it has a certain inhibitory activity on the three tumor cell lines A549, HepG2, and MCF-7.

[0101] Effects of ST-4 and its precursor candidate small molecule ST-2 on macrophages Fig.14 As shown, the results showed that ST-2 had no effect on the cell viability of iBMDMs and THP-1 cells; ST-4 exhibited dose-dependent toxic side effects on iBMDMs and THP-1 cells (the IC50 values ​​of ST-4 for iBMDMs and THP-1 cells were 10.15μM and 56.19μM, respectively), showing strong toxicity at high doses, while at the dosage concentration (2μM) and below, ST-4 had little effect on the cell viability of iBMDMs and THP-1 cells.

[0102] Example 3 Evaluation of the in vitro anti-inflammatory activity of the tetracyclic diterpene compound ST-4 provided by the present invention:

[0103] 1) Isolation and culture of mouse bone marrow-derived macrophages (BMDMs): In the animal room, take 6-week-old mice, kill them by cervical dislocation, remove the two hind legs of the mice with sterile scissors, remove the muscles and leave the leg bones, and place the mouse carcasses and other garbage in the mouse morgue. Take the mouse leg bones to the cell room clean bench, soak the scissors and tweezers in 75% alcohol, prepare culture medium, PBS, 20ml syringe and 0.65mm medical needle. Wash the mouse leg bones three times with PBS, fill the 20mL syringe with DMEM culture medium, replace it with a 0.65mm medical needle, grab the bones with tweezers, cut them from both ends with scissors, and then use a syringe to blow the bone marrow into a 50ml centrifuge tube, repeat several times until all the bone marrow is flushed out and the bones turn from red to white, centrifuge at 1500rpm for 5min. Discard the supernatant, resuspend with 1ml of red blood cell lysis buffer, and repeatedly blow, then let it stand for 2min to lyse the red blood cells, then add 9ml of normal DMEM medium for neutralization, 1500rpm, centrifuge for 5min. Discard the supernatant, resuspend with DMEM containing 20ng / mL M-CSF medium or L929 culture supernatant (40ml medium resuspended per mouse, L929 culture supernatant content 30%), and then transfer to non-treated culture dishes for culture (10ml per dish). After 6-7 days, the cell state can be observed, and it is long spindle-shaped, indicating that the state is good and can be used for subsequent experiments.

[0104] 2) Analysis of NLRP3 inflammasome activation and anti-inflammatory activity of compounds: BMDMs on day 6-7 of differentiation, discard the supernatant, wash once with PBS, add 10 ml of PBS containing 1% EDTA for digestion, and after 1-2 min, pipette the cells and transfer them to a 50 ml centrifuge tube and centrifuge at 1500 rpm for 10 min. Discard the supernatant, resuspend with 10 ml of culture medium, and then count to 5×10 6 / ml, then plated into 12-well plates, 1ml / well, overnight. Prepare Opti-MEM containing 1% FBS and 200ng / ml LPS (500μl per well), discard the supernatant, add the prepared culture medium for pre-stimulation, and the stimulation time is 3h. Add different concentrations of drugs for treatment for 30min. Add stimulants: Nigericin (10μM) or ATP (2.5mM), stimulate for 0.5h; or MSU (150μg / ml) stimulate for 4h. Sample collection: collect supernatant into 1.5ml EP tube; add 100μl sample buffer to cells for lysis, then transfer to a new 1.5ml EP tube and place in a 101℃ metal bath for 10min. The supernatant was centrifuged at 13000rpm for 5min to remove dead cells, and then transferred to a new 1.5ml EP tube. It can be directly used for Elisa detection of cytokines, or concentrated for WB. 500μl supernatant was added with 500μl methanol and 125μl chloroform, mixed, and centrifuged at 13000rpm for 5min. At this time, the solution was layered, and the middle layer was protein. The upper solution was removed, and 500μl methanol was added and mixed, and centrifuged at 13000rpm for 5min. At this time, the protein was precipitated in the lower layer. The supernatant was removed, and the residual methanol solution was removed by air for 5min. Then 80μl sample buffer was added, and the solution was placed in a 101℃ metal bath for 10min. It can be directly used for WB or stored at -20℃. Three replicate wells were set for each concentration, and PBS was set as a blank control, and 2uM concentration of Ori was set as a positive control to analyze the inhibitory effect of different concentrations of drugs on the expression and secretion level of IL-1β.

[0105] The effect of ST-4 on the activation of NLRP3 inflammasome was evaluated by inducing activation of NLRP3 inflammasome in mouse bone marrow-derived macrophages (BMDMs) and detecting the effect of ST-4 on the expression and secretion of related protein factors. The results of ELISA analysis showed that ST-4 could inhibit the secretion of inflammatory factors such as IL-1β and IL-18 in a dose-dependent manner ( Fig.15 a and c), but had no effect on IL-6 and TNF-α, the products of LPS-induced NF-κB signaling pathway activation ( Fig.15 d and e). WB analysis results also showed that ST-4 could inhibit the secretion of caspase-1 and IL-1β in a dose-dependent manner, but had no effect on pro-IL-1β and pro-caspase-1, the products of the NL-κB signaling pathway activated by LPS ( Fig.15b). The results showed that ST-4 could specifically inhibit the activation of NLRP3 inflammasome in a dose-dependent manner, but had no effect on the NF-κB signaling pathway. In addition, in BMDMs cells, ST-4 could also dose-dependently inhibit the secretion of IL-1β, a product of NLRP3 inflammasome activation activated by ATP and MSU ( Fig.16 ). This indicates that ST-4 can inhibit the activation of NLRP3 inflammasome caused by a variety of NLRP3 inflammasome activators.

[0106] The activation process of NLRP3 inflammasome is divided into two stages, namely, the activation stage of NF-κB signaling pathway induced by LPS and the assembly and activation stage of NLRP3 inflammasome with NLRP3 protein as the skeleton structure induced by the second stimulus signal (Nigericin, ATP, MSU, etc.). By comparing the intervention with ST-4 before adding LPS and the intervention with ST-4 after adding LPS, the effects of two different ST-4 intervention methods on the expression and secretion of products activated by NF-κB signaling pathway were detected. The results are shown in Fig.17 As shown. The results showed that adding ST-4 intervention before or after LPS treatment of BMDMs cells had no effect on the activation of the NF-κB signaling pathway. The expression of NLRP3, ASC, pro-caspase-1, and pro-IL-1β protein precursors, the secretion of inflammatory factor TNF-α, and the secretion of IL-1β and caspase-1, the products of NLRP3 inflammasome activation, did not change. This indicates that ST-4 has no effect on the LPS-induced activation of the NF-κB signaling pathway, but specifically inhibits the assembly and activation stage of the NLRP3 inflammasome with NLRP3 protein as the skeleton.

[0107] Example 4: Verification test on the in vivo anti-inflammatory disease effect of the tetracyclic diterpene compound ST-4 provided by the present invention.

[0108] The experimental method for verifying the effect of anti-inflammatory related diseases is as follows:

[0109] 1) Establishment of MSU-induced mouse peritonitis and drug treatment experiments

[0110] The experimental method is: 6-8 week old SPF male C57BL / 6 mice (purchased from Hubei Provincial Center for Disease Control and Prevention) and NLRP3 - / -Gene-deficient mice (gifted by Professor Zhang Anding's team from the College of Animal Science and Technology of Huazhong Agricultural University) were weighed and then divided into groups so that each group was similar. ST-4 (20 mg / kg, dissolved in DMSO) was injected intraperitoneally in the experimental group, and the same volume of solvent was injected in the control group. Sterile MSU crystals (1 mg MSU, dissolved in 0.5 mL sterile PBS) were injected intraperitoneally 0.5 h later. Blood was collected from the eyeballs 6 h later, and the blood was allowed to stand at room temperature for 60 min, then centrifuged at 5000 rpm for 10 min to collect serum. Mice were killed by cervical dislocation, and the peritoneal cavity was first rinsed with 1 ml sterile PBS. After the peritoneal lavage fluid was removed, it was centrifuged at 3000 rpm for 5 min. The supernatant was used to detect cytokines, and the precipitated cells were used to detect the number of neutrophils. The peritoneal cavity was rinsed with 9 ml sterile PBS again, the peritoneal lavage fluid was removed, the supernatant was removed by centrifugation, and the precipitated cells were mixed with the cells in the previous step for routine blood analysis of neutrophils.

[0111] 2) Establishment of MSU-induced gouty arthritis in mice and drug treatment experiments

[0112] The experimental method is: 6-8 week old SPF male C57BL / 6 mice (purchased from Hubei Provincial Center for Disease Control and Prevention) and NLRP3 - / - Gene-deficient mice (gifted by Professor Zhang Anding's team from the College of Animal Science and Technology, Huazhong Agricultural University) were weighed and then divided into groups so that each group was similar, and the circumference of the left and right ankle joints was measured. ST-4 (20 mg / kg, dissolved in DMSO) was injected into the left ankle joint of the experimental group, and the same volume of solvent was injected into the left ankle joint of the control group. 30 minutes later, MSU crystals (0.5 mg, dissolved in 20 μL sterile PBS) were injected into the left ankle joint, and the same volume of sterile PBS was injected into the right ankle joint. The circumference of the left and right ankle joints was measured after 1, 6, 12, and 24 hours, and then the mice were killed by cervical dislocation. The left ankle joint was removed and placed in a 12-well plate containing 200 μL opti-MEM (1% double antibody) for 2 hours. The culture supernatant was detected for IL-1β by ELISA, and the relevant data were processed according to the measured joint circumference.

[0113] 3) Establishment of obese mouse model of metabolic syndrome and drug treatment experiments

[0114] The breeding method was as follows: 6-week-old SPF-grade C57BL / 6 mice (purchased from Hubei Provincial Center for Disease Control and Prevention) and NLRP3 - / -Gene-deficient mice (gifted by Professor Zhang Anding's team from the College of Animal Science and Technology of Huazhong Agricultural University) were kept in an SPF animal room at room temperature of 22°C at a rate of 4 mice / cage. They were fed with a 60% calorie high-fat diet (purchased from Bio-medicine) for 14-16 weeks. The mice were free to eat, the bedding was changed every two days, and the body weight and blood glucose were tested weekly. When the blood glucose was greater than 11mmol / L and the body weight was greater than 42g, the drug was started to be administered. The drug was dissolved in DMSO solvent and administered by intraperitoneal injection at three doses of 2.5, 5, and 10mg / kg for 42 consecutive days. The injection volume was 25uL per day. At the same time, solvent (25ul DMSO) and 3mg / kg positive drug (Ori) controls were set. The food intake and body weight changes of each group of mice were measured every day. Blood routine and blood biochemical parameters were monitored on the 0th and 42nd days. Glucose tolerance (GTT) and insulin sensitivity (ITT) experiments were also performed. The blank group and ST-4 treated group mice were pathologically dissected to observe the changes in organs before and after the drug treatment, and samples were taken to prepare pathological sections.

[0115] Establishment of lean mouse model and drug treatment experiments

[0116] The feeding and experimental methods were as follows: 6-week-old SPF male C57BL / 6 mice (purchased from Hubei Provincial Center for Disease Control and Prevention) were housed in an SPF animal room at room temperature of 22°C at a rate of 4 mice / cage, and were fed with ordinary mouse feed for 2 weeks. The mice were free to eat, and the bedding was changed every two days. The body weight and blood sugar were tested weekly. The drug was administered after the body weight reached 22g. The drug was dissolved in DMSO solvent and administered by intraperitoneal injection with an injection volume of 25uL per day. Solvent and positive drug controls were also set up. The food intake and body weight of each group of mice were monitored every day.

[0117] Establishment of a long-term ST-4 toxicity test model in lean mice

[0118] The experimental method is as follows: 6-8 week old C57BL / 6 mice were taken, weighed, and random blood sugar was tested. Mice with similar body weight and blood sugar were selected for grouping so that each group was similar. The experimental group mice were treated with solvent for 3 days (25μL DMSO / day) and then injected with ST-4 (10mg / kg; 25μL each time). The control group was injected with the same volume of solvent. The drug was administered at 18:00 every day for 90 consecutive days. The weight and food intake of the mice were recorded every day. After the experiment, blood was collected from the eyeballs. Half of the blood was treated with anticoagulant (Disodium EDTA) and placed on ice for routine blood tests; the other half of the blood was left at room temperature for 60 minutes, and then centrifuged at 5000rpm for 10 minutes to collect serum. Serum was used for blood biochemical tests, including the levels of alkaline aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatinine (CRE), urea (UREA) and total bilirubin (T-BIL).

[0119] The acute peritonitis model in mice was induced by MSU, and ST-4 was injected intraperitoneally to intervene. The levels of IL-1β in mouse serum and peritoneal effusion and the levels of neutrophils in peritoneal effusion were detected to evaluate the therapeutic effect of ST-4 on the acute peritonitis model induced by MSU. Fig.18 As shown, the results showed that ST-4 had a significant alleviating effect on the MSU-induced acute peritonitis pathological model in mice, and could significantly reduce the level of IL-1β inflammatory factors in mouse serum and peritoneal effusion, as well as the number of neutrophils in peritoneal effusion. In NLRP3 gene-deficient mice, ST-4 did not show this effect. The results indicate that the inhibitory effect of ST-4 on MSU-induced acute peritonitis in mice depends on the NLRP3 inflammasome.

[0120] Acute gouty arthritis in mice was induced by joint injection of MSU crystals, and the therapeutic effect of ST-4 on the acute gouty arthritis pathological model in mice was evaluated by intervening ST-4 in the size of joint swelling and intra-articular IL-1β levels. Fig.19 As shown, the results showed that ST-4 could alleviate the pathological state of acute gouty arthritis in mice induced by MSU, which was manifested by a significant reduction in joint swelling and a significant decrease in the inflammatory factor IL-1β in the joints. However, ST-4 had no effect on NLRP3-deficient mice. The results showed that ST-4 could alleviate acute gouty arthritis in mice induced by MSU, and this effect depended on the NLRP3 inflammasome.

[0121] Obesity and type 2 diabetes models were induced in mice by HFD. The mice were fed HFD for 14-16 weeks, and the mice with successful modeling were divided into groups. ST-4 was injected intraperitoneally for intervention, and the pharmacological effect of ST-4 on HFD-induced metabolic disorders in mice was evaluated by detecting physiological and biochemical indicators of mice. The results showed that intraperitoneal injection of ST-4 could significantly reduce the body weight and food intake of HFD-induced obese mice ( Fig. 20 ). In addition, by analyzing the blood glucose data of the model group and the ST-4 administration group, we found that ST-4 intervention can significantly reduce the fed blood glucose and fasting blood glucose of HFD-induced type 2 diabetic mice, and can also significantly improve the blood glucose tolerance and insulin sensitivity of HFD-induced type 2 diabetic mice ( Fig.21 In addition, H&E staining was used to analyze the morphology of liver tissue and white adipose tissue cells in mice and found that ST-4 administration intervention could significantly reduce the accumulation of fat in the liver tissue of HFD-induced obese mice ( Fig. 22 b), and after ST-4 treatment, the adipocytes in the adipose tissue of mice were smaller and more compact than those in the model group mice ( Fig. 22 c), indicating that ST-4 administration can improve the pathological state of HFD-induced obese mice.

[0122] ST-4 can affect the body weight and food intake of HFD-induced obese mice and type 2 diabetic mice. Does it have any effect on the body weight and food intake of normal mice fed with NCD? The effect of ST-4 on lean mice fed with NCD was studied by intraperitoneal injection. Fig.23 As shown, the results showed that ST-4 had no effect on the body weight and food intake of normal mice fed with NCD.

[0123] NLRP3 by HFD feeding - / - Gene-deficient mice were induced to induce metabolic disorders, and ST-4 was injected intraperitoneally for drug intervention. The physiological and biochemical indices of the model group and the ST-4 administration group were tested to evaluate the effect of ST-4 on HFD-induced NLRP3 - / - The results showed that the body weight of the high-dose ST-4 treatment group decreased, while the body weight of the low-dose ST-4 group did not change significantly ( Fig.24 a and b), and the corresponding change was the change in food intake. The food intake of the high-dose group was significantly reduced, while the food intake of the low-dose group was significantly increased ( Fig.24 c) Effect of ST-4 on HFD-induced NLRP3 - / - The results of the effects on blood sugar in mice with gene-deficient metabolic disorders are as follows Fig.25 The results showed that ST-4 treatment had an effect on HFD-induced NLRP3 - / - Fasting blood glucose in gene-deficient metabolic disorder mice ( Fig.25a) and fed blood glucose ( Fig.25 b) No significant effect. Meanwhile, GTT and ITT analysis showed that the blood glucose tolerance of ST-4 treatment group and model group ( Fig.25 c) and insulin sensitivity ( Fig.25 In addition, H&E staining results of liver tissue and adipose tissue showed that ST-4 had an inhibitory effect on HFD-induced NLRP3 - / - There was no significant effect on liver tissue and adipose tissue in the gene-deficient metabolic disorder mice ( Fig.26 ).

[0124] The effect of ST-4 on the level of systemic inflammation in mice induced by HFD was evaluated by detecting the levels of various inflammatory factors in the serum, liver and adipose tissue of mice in the metabolic disorder model group and the ST-4 treatment group. The results showed that the IL-1β content in the serum, liver and adipose tissue of C57BL / 6 mice in the ST-4 treatment group was significantly reduced. WB analysis of adipose tissue also showed that ST-4 could significantly inhibit the activation of caspase-1, while ST-4 could significantly inhibit the activation of NLRP3. - / - Gene-deficient mice had no effect ( Fig. 27 In addition, we also analyzed the levels of other inflammatory factors in the serum and tissues of mice with metabolic disorders induced by HFD, and the results also showed consistent effects. ST-4 can also significantly reduce the levels of inflammatory factors TNF-α and chemokine MCP-1 in the serum, liver and adipose tissue of pathological model mice, but has no effect on NLRP3. - / - Gene-deficient mice had no effect ( Fig.28 ). The results showed that ST-4 could inhibit NLRP3 inflammasome-dependent chronic inflammation and alleviate the inflammatory state of HFD-induced metabolic disorder model mice.

[0125] The long-term toxicity of ST-4 was evaluated by intraperitoneal injection of solvent or ST-4 (10 mg / kg) into normal mice for up to 3 months, and the physiological and biochemical levels of the solvent group and the ST-4 treatment group were detected. The results of the physiological indicators such as body weight, food intake, fasting blood glucose and fed blood glucose in the solvent group and the ST-4 treatment group showed that there was no significant difference in physiological indicators such as body weight, food intake and blood glucose between the solvent group and the ST-4 treatment group ( Fig.29 ). In addition, the levels of various biochemical factors such as alkaline aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatinine (CRE), urea (UREA) and total bilirubin (T-BIL) in the serum of the solvent group and the ST-4 treatment group were detected by blood biochemistry. The results also showed that there was no significant difference in the levels of various biochemical factors in the serum of the solvent group and the ST-4 treatment group ( Fig.30The results showed that ST-4 had no toxicity to normal mice at the injection dose (10 mg / kg).

[0126] It will be easily understood by those skilled in the art that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A drug screening method based on structural fragments, characterized in that: The following steps are involved: (1) Using a molecule to be improved with specific biological activity as a lead molecule, fragmenting its molecular structure into structural fragments, screening out the mother core structure as a mother core screening marker structural fragment, and screening out the multi-ring structure as a binding screening marker structural fragment; (2) using the parent core screening marker structural fragment obtained in step (1) and one or more combined screening marker structural fragments as screening conditions, respectively, and searching in a natural product database for a set of compounds containing all screening marker structural fragments of the screening conditions as a set of candidate raw material molecules; (3) selecting one or more raw material molecules from the raw material molecule set obtained in step (2), comparing them with the lead molecule obtained in step (1), and performing functional group modification on the raw material molecules to obtain one or more designed molecules, so that the structural similarity between the designed molecules and the lead molecule is higher than the structural similarity between the raw material molecules and the lead molecule.

2. The drug screening method based on structural fragments according to claim 1, characterized in that: A polycyclic structure is a polycyclic structure that shares 3 or more atoms.

3. The drug screening method based on structural fragments according to claim 2, characterized in that: A polycyclic structure is a polycyclic structure that shares 3 or more carbon atoms.

4. The drug screening method based on structural fragments according to claim 2, characterized in that: The polycyclic structure is a polycyclic structure that shares 6 or more carbon atoms or a polycyclic structure that shares 8 or more carbon atoms.

5. The drug screening method based on structural fragments according to claim 1, characterized in that: The raw material molecules selected from the raw material molecule set in step (3) are: Based on the indicators that affect the prospects of drug development, raw material molecules are selected according to the principle of giving priority to those with better drug development prospects.

6. The drug screening method based on structural fragments according to claim 5, characterized in that: The indicator affecting the drug development prospects is the biological content in the host.

7. The drug screening method based on structural fragments according to claim 1, characterized in that: Step (3) is to make the structural similarity between the designed molecule and the lead molecule higher than the structural similarity between the raw material molecule and the lead molecule, and the specific steps are as follows: The active functional groups of the lead molecule are determined by analyzing the physiological model or molecular docking model of the lead molecule, and compared with the raw material molecule, different active functional groups are obtained, and the different functional groups are constructed at the corresponding positions of the mother nucleus of the raw material molecule.

8. The designed molecule obtained by the drug screening method based on structural fragments according to any one of claims 1 to 7, characterized in that: It has a core structure shown in formula (1) and a polycyclic structure shown in formula (2); 9. The designer molecule according to claim 8, characterized in that It is: 15-carbonyl-stevioside.

10. The use of the designer molecule according to claim 8 or 9, characterized in that: It can be used to prepare anti-inflammatory drugs or anti-metabolic syndrome drugs.

11. The use of the designer molecule according to claim 10, characterized in that It can be used to prepare anti-acute peritonitis drugs, anti-acute gouty arthritis drugs, anti-chronic inflammation drugs, and for the preparation of NLRP3 inflammasome-mediated inflammatory-related disease treatment drugs including neurodegenerative diseases.

12. The use of the designer molecule according to claim 10, characterized in that It is used to prepare drugs for treating obesity and type 2 diabetes.